Tag: immunotherapy
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
— Existing investors and new investor Double Point Ventures join forces to support ImmunOs Therapeutics
— Investment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a Series C financing round of $11 million. The round was led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures as well as other existing investors. In conjunction with the round, Steve Tregay, PhD, Managing General Partner of Mission BioCapital, has joined the Company’s Board of Directors.
ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
– Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Michael A. Curran, PhD, has been appointed Chairman of the Company´s Scientific Advisory Board. In addition to Dr. Curran, Taha Merghoub, PhD, Ulf Petrausch, MD, and Paul Bowness, MD, PhD, currently serve as Scientific Advisors to ImmunOs.
Allero Therapeutics Receives EIC Horizon Grant to Advance Treatment of Celiac Disease
– Specific OroMucosal ImmunoTherapy (SOMIT) for celiac disease patients supported with EUR 2.5mn funding
Allero Therapeutics BV, a Dutch oromucosal immunotherapy company, today announced that the Company has received a EUR 2.5 million EIC Horizon Grant provided by the European Commission to advance novel treatments for celiac disease patients. The program is based on Allero´s proprietary SOMIT (Specific OroMucosal ImmunoTherapy) platform technology for the treatment of antigen-driven immune disorders.
ImmunOs Therapeutics Raises $74 Million Series B Financing Round
– New investors Samsara, Lightspeed, Gimv, and Mission BioCapital further strengthen investor base and expand transatlantic footprint
– Company establishes U.S. subsidiary to accelerate international operations
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL Capital, PEAK6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq. Read more…